Bravura is a good long term investment because of the niche it occupies and market footprint. Although at this price it's already too expensive given the current macro conditions. The clients are all under severe pressure to cut costs and technology expenditure will be kept to a minimum other than compliance and regulatory projects.
- Forums
- ASX - By Stock
- Price
Bravura is a good long term investment because of the niche it...
Featured News
Add BVS (ASX) to my watchlist
|
|||||
Last
$1.06 |
Change
0.005(0.48%) |
Mkt cap ! $473.0M |
Open | High | Low | Value | Volume |
$1.04 | $1.07 | $1.04 | $454.1K | 429.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 200 | $1.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.06 | 4448 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 1.050 |
1 | 3130 | 1.045 |
2 | 6728 | 1.040 |
2 | 29483 | 1.030 |
1 | 4000 | 1.020 |
Price($) | Vol. | No. |
---|---|---|
1.060 | 4448 | 3 |
1.065 | 18589 | 2 |
1.080 | 16338 | 2 |
1.095 | 15500 | 1 |
1.120 | 2685 | 2 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
BVS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online